icosapent ethyl / Generic mfg. - LARVOL DELTA

Icosapent ethyl in clinical practice: the Spanish experience (ESC-WCC 2025) - "Sponsored by Amarin"

Clinical • Cardiovascular

Icosapent ethyl reduces cardiovascular risk across apolipoprotein b and fasting triglyceride rich lipoprotein levels (ESC-WCC 2025) - No abstract available

Cardiovascular • APOB

Effects of icosapent ethyl on risk and duration of hospitalizations and death in REDUCE-IT (ESC-WCC 2025) - No abstract available

Clinical • Cardiovascular

Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM (ESC-WCC 2025) - No abstract available

Cardiovascular

Icosapent ethyl eligible patients following acute coronary syndrome are at increased risk of myocardial re-infarction: Data from CALLINICUS-Hellas registry (ESC-WCC 2025) - No abstract available

Clinical • Acute Coronary Syndrome • Cardiovascular

The approach to triglyceride levels in patients with coronary heart disease. (PubMed, Eur J Intern Med) - "Most CHD patients have controlled TG levels. However, additional attention should be given to the diabetic ones. Further education and strict policy are needed."

Journal • Cardiovascular • Coronary Artery Disease • Diabetes • Dyslipidemia • Heart Failure • Hypertriglyceridemia • Metabolic Disorders • Severe Hypertriglyceridemia

Icosapent ethyl: From the REDUCE-IT trial to clinical practice. (PubMed, Clin Investig Arterioscler) - "This analysis suggests a transversal therapeutic approach, based on both LDL cholesterol and triglycerides, for patients at very high cardiovascular risk to achieve an effective prevention. Furthermore, among patients in secondary prevention, treatment with IPE should focus on those with the highest vascular risk (recent acute coronary syndrome, post-infarction, angioplasty, and coronary bypass grafting)."

Journal • Review • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Dyslipidemia • Hypertriglyceridemia

Evidence on cardiovascular prevention with icosapent ethyl. (PubMed, Clin Investig Arterioscler) - "This authorization comes as a consequence of the clinical benefit observed in the "Reduction of Cardiovascular Events with Icosapent Ethyl Intervention Trial", in which icosapent ethyl demonstrated - compared to placebo - a 25% reduction in the relative risk of cardiovascular morbidity and mortality, a result consistent and independent of other variables in prespecified analyses and hypothesis generating in post-hoc analyses of several patient profiles. Although the mechanism of action for such benefit is not definitively established, it is known that it acts at different levels in the continuum of atherosclerotic cardiovascular disease (lipid-lowering, vascular endothelium and membrane protection, anti-inflammatory, atherosclerotic plaque stabilizing and antithrombotic effects) and that final anti-atherosclerotic action in the coronary territory has been demonstrated in the study "Effect of Vascepa on Improving Coronary Atherosclerosis in People With High..."

Journal • Review • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Hypertriglyceridemia

Cardiovascular prevention studies in a population with hypertriglyceridemia. (PubMed, Clin Investig Arterioscler) - "The recommendation, especially the former, is limited to some subjects already treated with statins and with optimal LDL cholesterol levels in whom elevated triglyceride levels persist. As an exception, only purified icosapent ethyl at a high dose (4g daily) has demonstrated a reduction in cardiovascular morbidity and mortality and has been authorized for this indication, following the results of the REDUCE-IT trial."

Journal • Review • Atherosclerosis • Cardiovascular • Dyslipidemia • Hypertriglyceridemia

Estimate and prognosis of patients who are candidates for treatment with eicosapentaenoic acid after an acute coronary syndrome. (PubMed, J Clin Lipidol) - "Approximately 20% of patients discharged after an ACS could be candidates for IPE, and this subset of patients are at higher risk of MACE or death."

Journal • Acute Coronary Syndrome • Cardiovascular • Congestive Heart Failure • Dyslipidemia • Heart Failure

Resolving the Metabolic Puzzle, Tirzepatide's Multifaceted Benefits in Partial Lipodystrophy (ENDO 2025) - "Metreleptin is an approved therapy for GLD, but there are no FDA-approved treatments for PLD...Medications included insulin, metformin XR 2000 mg daily, empagliflozin 25 mg daily, rosuvastatin 20 mg daily, icosapent ethyl 4 grams daily, and fenofibrate 160 mg daily... The patient exhibited profound and multifaceted metabolic improvement following initiation of tirzepatide treatment. These improvements were much greater than previously reported with GLP-1 receptor agonists in PL, suggesting a unique role for GIP receptor agonism in addressing the complex metabolic dysregulation associated with this disorder. The observed clinical benefits, including improved glycemic control, triglyceride improvement, reduced insulin dependence, and improved steatosis have significant implications for the management of this complex and challenging condition."

Dyslipidemia • Genetic Disorders • Hepatology • Hypertriglyceridemia • Hypoglycemia • Lipodystrophy • Metabolic Disorders • Obesity • Obstructive Sleep Apnea • Pancreatitis • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Impact of GLP-1 Analogs vs. Lipid Lowering Agents on Risk for Acute Pancreatitis in Hypertriglyceridemia: A TriNetX Analysis (ENDO 2025) - "There were 21,106 patients receiving treatment with a GLP-1 analog (Cohort A) and 296,961 patients taking lipid lowering agents which we defined as atorvastatin, rosuvastatin, pravastatin, simvastatin, fenofibrate, ezetimibe, icosapent ethyl, evolocumab (Cohort B). Furthermore, it may reduce mortality for patients who have failed other modalities for weight loss, which is consistent with our findings. Ongoing research is essential to understand the long-term outcomes of GLP-1 analog therapy."

Dyslipidemia • Genetic Disorders • Hypertriglyceridemia • Obesity • Pancreatitis • Severe Hypertriglyceridemia

Giant Pancreatic Pseudocyst as a complication of Hypertriglyceridemia-Induced Pancreatitis (ENDO 2025) - "On day tenth, given clinical and biochemical improvement and a multidisciplinary team discussion, patient was discharged on metformin, fenofibrate, atorvastatin, pioglitazone, and vascepa, with plan for GI follow-up for possible necrosectomy. This case reports rare occurrence of HTG-induced necrotizing pancreatitis with the formation of giant pancreatic pseudocyst. It also illustrates the importance of timely intervention and proper management of severe hypertriglyceridemia, to reduce the risk of complications including necrotizing pancreatitis and pseudocyst. Long-term management should be focused on alleviating the effects of metabolic syndrome by addressing related factors like diabetes and obesity."

Diabetes • Dyslipidemia • Genetic Disorders • Hypertriglyceridemia • Metabolic Disorders • Obesity • Pain • Pancreatitis • Severe Hypertriglyceridemia

Breaking the Triglyceride Barrier: A Case of Severe Hypertriglyceridemia Management (ENDO 2025) - "Pharmacologic therapy included continuation of rosuvastatin 40 mg, fenofibrate 160 mg, and ezetimibe 10 mg. Patient was also started on Icosapent ethyl 2 g twice daily and Levothyroxine (LTX) was increased from 125 mcg to 150 mcg due to an elevated TSH level of 10.4 µIU/mL with a free T4 of 1.0 ng/dL...The patient was also prescribed evolocumab, but insurance restrictions required specialist approval...For symptomatic severe HTG cases, particularly with acute pancreatitis, IV insulin and therapeutic plasma exchange are key treatment options. Further research is needed to assess long-term outcomes and the role of emerging therapies in severe HTG management."

Clinical • Cardiovascular • Dyslipidemia • Endocrine Disorders • Hypertension • Hypertriglyceridemia • Obesity • Pancreatitis • Severe Hypertriglyceridemia

Evinacumab as an Effective Treatment Option for Refractory Hypertriglyceridemia (ENDO 2025) - "Despite using atorvastatin 80 mg daily, fenofibrate 162 mg daily, icosapent ethyl 2 g twice daily, and evolocumab 140 mg every 2 weeks, she continued to have hypertriglyceridemia. Evinacumab may be an effective alternative agent for the management of chronic hypertriglyceridemia based on the robust effects seen in our patient. Future research is needed to explore evinacumab's therapeutic targets beyond LDL-C to better modify risk factors for atherosclerosis, as well as CAV progression in heart transplant recipients."

Atherosclerosis • Cardiomyopathy • Cardiovascular • Diabetes • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Homozygous Familial Hypercholesterolemia • Hypertriglyceridemia • Metabolic Disorders • Pancreatitis • Severe Hypertriglyceridemia • Type 2 Diabetes Mellitus • ANGPTL3 • APOB

Hypercholesterolemia management in a patient with mitochondrial encephalomyopathy lactic acidosis, and stroke-like episodes (NLA 2025) - "However, one case study in a patient with mitochondrial myopathy due to heteroplasmic mitochondrial DNA missence mutation in MTCO1 gene (m.7671T>A) demonstrated stable CK levels without recurrence of myalgia while taking alirocumab 75 mg every 2 weeks, ezetimibe 10 mg daily, marine omega 3 fatty acids daily, and 145 mg of micronized fenofibrate every 2 days (Cicero et al., 2020)...He had a history of hypercholesterolemia with debilitating myalgias on simvastatin, atorvastatin and rosuvastatin prior to MELAS diagnosis...Ezetimibe 10 mg daily and icosapent ethyl 4 g daily was initiated and well tolerated...Evolocumab 140 mg subcutaneous every 14 days was prescribed and tolerated without side effects...Conclusions This case highlights consideration for MELAS in young adults with stroke-like episodes and demonstrates successful use of non-statin lipid lowering medications to manage hypercholesterolemia. Further research is necessary in this patient population."

Clinical • Cardiovascular • CNS Disorders • Dyslipidemia • Metabolic Disorders • Musculoskeletal Pain • Myositis • Pain

Impact of polygenic risk score on the use of lipid-lowering therapy in primary prevention for coronary artery disease (NLA 2025) - "Lipid-lowering therapy included statins, ezetimibe, PCSK9 inhibitors, bempedoic acid, and icosapent ethyl. Lastly, a significantly greater proportion of high-risk PRS patients were prescribed statin therapy compared to low-risk PRS patients, despite a higher rate of pre-PRS prescriptions. While our findings suggest PRS influences LLT for primary prevention of CAD, further investigation is needed to demonstrate statistically robust correlations between PRS and clinical decision-making."

Cardiovascular • Coronary Artery Disease

Lipoprotein apheresis to address residual risk in recurrent atherosclerotic events (NLA 2025) - "At this time, icosapent ethyl was added and his lipid profile was controlled with apolipoprotein B of 60 mg/dL...PCSK9 inhibitor was denied again so bempedoic acid was added...Two days after surgery, evolocumab was approved and initiated...For our patient, delays in PCSK9 inhibitor and apheresis initiation likely influenced disease progression. Lipoprotein apheresis has demonstrated a reduction in cardiovascular events."

Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Diabetes • Dyslipidemia • Familial Hypercholesterolemia • Genetic Disorders • Metabolic Disorders • Peripheral Arterial Disease • Type 2 Diabetes Mellitus • APOB

Successful lipid-lowering in statin and PCSK9i intolerant patient with mixed hyperlipidemia: A case study of inclisiran as a therapeutic option. (NLA 2025) - "Methods Based on her history of pancreatitis, we stopped the rosuvastatin 5 mg, and started icosapent ethyl 2 gm BID with gemfibrozil 600 mg twice daily...Ezetimibe 10 gm was added but the patient had muscle pain. Alirocumab 150 mg twice weekly was started but patient developed sinusitis that persisted even on reduced dose...However, more long-term studies are needed to assess the impact on cardiovascular outcomes. Our case demonstrates the presence of multiple options available to treat mixed hyperlipidemia."

Case study • Clinical • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Heart Failure • Hypertension • Hypertriglyceridemia • Immunology • Mixed Hyperlipidemia • Musculoskeletal Pain • Otorhinolaryngology • Pain • Pancreatitis • Respiratory Diseases • Sinusitis

Attrition of adipose: Type 2 familial partial lipodystrophy manifesting in severe premature CAD (NLA 2025) - "She was prescribed icosapent ethyl and introduced to a lipodystrophy patient advocacy group...Metreleptin (recombinant leptin analog) is approved for severe generalized lipodystrophy and under investigation for partial lipodystrophy, while a similar leptin receptor agonist trial was terminated. LD expressed gratitude that knowing her diagnosis and connecting with others made her feel less alone and more supported. This case highlights the importance of considering lipodystrophy in the differential diagnosis of patients presenting with atypical features of classical metabolic syndrome and suggestive adipose distribution."

Cardiomyopathy • Cardiovascular • Coronary Artery Disease • Diabetes • Dyslipidemia • Hypertriglyceridemia • Lipodystrophy • Metabolic Disorders • Obesity • Pancreatitis • Severe Hypertriglyceridemia • Type 1 Diabetes Mellitus • LEP • LEPR • LMNA

Impact of grant-funded carotid intima-media thickness ultrasound on cardiovascular risk assessment and management in an underserved population (NLA 2025) - "Lipid-lowering therapy included statins, ezetimibe, PCSK9 inhibitors, bempedoic acid, and icosapent ethyl. These findings emphasize the public health impact of CIMT ultrasound in this population. Removing financial barriers to accessing this tool is essential for optimizing preventive cardiovascular care."

Clinical • Grant • Atherosclerosis • Cardiovascular

Moving triglycerides off the “back burner”: Developing a tailored approach to managing ASCVD risk in post-ACS patients (NLA 2025) - "The 2018 NLA scientific statement recommends additional treatment such as icosapent ethyl (IPE) for patients at high risk for atherosclerotic cardiovascular disease (ASCVD), which has shown a reduction in recurrent Major Adverse Cardiovascular Events (MACE)...Transcript analysis of the deliberative engagement session highlighted preferred implementation strategies if the system was to implement a standard protocol for HTG and ASCVD care management, helping finalize the preliminary implementation strategy toolkit for the pilot. Conclusions Rigorous human-centered design methods helped inform each step of the pre-implementation phase, producing an acceptable, context-appropriate, and feasible implementation strategy toolkit, to assist with HTG and ASCVD care standardization for patients post-ACS."

Clinical • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Dyslipidemia • Hypertriglyceridemia

Medical nutrition therapy helps lower triglycerides in patients with chylomicronemia and type 2 diabetes: A case series (NLA 2025) - "Relevant medications included insulin and icosapent ethyl. Fenofibrate was initiated on the same day as MNT...Relevant medications included metformin and over-the-counter omega-3 fatty acids.Genetic testing was not performed...MNT is an important adjunct to medical therapy for managing severe hypertriglyceridemia and diabetes. Ongoing, frequent support is necessary to improve adherence and customize nutrition therapy to individual preferences and needs"

Clinical • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Diabetes • Dyslipidemia • Familial Chylomicronemia Syndrome • Hypertriglyceridemia • Metabolic Disorders • Pancreatitis • Severe Hypertriglyceridemia • Type 2 Diabetes Mellitus

Prevalence of REDUCE-IT trial eligible patients in a coronary disease follow-up program (HEART FAILURE 2025) - "Approximately 8% of patients in a structured coronary follow-up program were eligible for REDUCE-IT trial interventions. Real-world identification of such patients enables tailored therapeutic strategies and highlights the need for further research on the implementation and impact of icosapent ethyl in clinical practice."

Clinical • Acute Coronary Syndrome • Cardiovascular • Dyslipidemia

Icosapent ethyl reduces arterial thrombosis by inhibition of cyclooxygenase-1-induced platelet reactivity. (PubMed, Sci Transl Med) - "In patients with cardiovascular disease, switching from 2 grams of EPA twice daily to 1 gram of docosahexaenoic acid (DHA) (460 milligrams of EPA and 380 milligrams of DHA) once daily completely blunted the platelet inhibition achieved by EPA. Our results may partially explain contradictory results with different ω-3 PUFA formulations in clinical trials."

Journal • Cardiovascular • Hematological Disorders • Thrombosis